The PRKDC Knockout A-549 Cell Line is a human CRISPR/Cas9-engineered cell model in which the PRKDC gene has been disrupted to eliminate functional DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression. This stable knockout model is generated in the A-549 background, a human alveolar epithelial adenocarcinoma cell line, and is intended for in vitro studies of DNA repair, stress signaling, and therapeutic response. Because PRKDC is a central mediator of DNA double-strand break repair, this edited cell line provides a defined system for interrogating non-homologous end joining (NHEJ) deficiency in a pulmonary epithelial cancer context.
A-549 cells are derived from human lung adenocarcinoma and exhibit alveolar type II-like epithelial characteristics, making them a widely used model in respiratory biology, lung cancer research, and drug response studies. Their epithelial barrier-forming phenotype and relevance to pulmonary tumor biology support investigation of cancer-associated stress responses, genotoxic injury, and treatment sensitivity. In experimental settings, A-549 cells are frequently used to examine mechanisms linked to radiation exposure, oxidative stress, and cytotoxic drug action, providing a useful host background for studying how DNA repair defects influence tumor cell behavior.
PRKDC encodes DNA-PKcs, a serine/threonine kinase that is recruited to DNA double-strand breaks by the XRCC6/KU70-XRCC5/KU80 DNA end-binding complex. DNA-PKcs functions with XRCC4, LIG4, XLF/NHEJ1, DCLRE1C/Artemis, PAXX, and TP53BP1 to promote DNA end synapsis, end processing, and ligation during NHEJ. PRKDC is activated downstream of DNA double-strand breaks induced by ionizing radiation, radiomimetic agents, and reactive oxygen species, and it participates in signaling crosstalk with ATM and ATR. Loss of PRKDC can alter phosphorylation-associated damage signaling involving H2AX, CHEK2, and TP53, reduce DNA end joining efficiency, and shift cellular outcomes toward cell-cycle arrest or apoptosis. These processes are directly relevant to lung cancer biology, solid tumor radioresistance, genomic instability, and therapeutic response.
In the A-549 host background, PRKDC knockout creates a mechanistically informative model for examining how impaired NHEJ modifies epithelial tumor cell responses to DNA damage and replication stress. The combination of a clinically relevant lung adenocarcinoma cell context with disruption of a core repair kinase is useful for studying pathway dependence, compensatory DNA damage signaling, and determinants of sensitivity to radiation or DNA-damaging compounds. This system can also support analysis of p53-associated stress signaling and broader genome stability phenotypes in pulmonary cancer cells.
Applications include western blotting or RT-qPCR to assess PRKDC pathway disruption; immunofluorescence analysis of gamma-H2AX and 53BP1 foci after irradiation; phospho-signaling studies examining ATM, ATR, CHEK2, H2AX, and TP53 pathway responses; comet assays to quantify DNA break persistence; and reporter assays measuring NHEJ activity. The model is also suited to clonogenic survival assays following ionizing radiation, apoptosis measurements, flow cytometric cell-cycle profiling, co-immunoprecipitation of repair complexes, RNA-seq-based transcriptional analysis, and drug sensitivity studies designed to identify synthetic lethal interactions or genotype-dependent responses to genotoxic therapies. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.
